Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.45 |
| ▸ | MMP9 | P14780 | 4/20 | 0.45 |
| ▸ | MMP8 | P22894 | 4/20 | 0.45 |
| ▸ | MMP12 | P39900 | 4/20 | 0.45 |
| ▸ | MMP13 | P45452 | 4/20 | 0.45 |
| ▸ | MMP14 | P50281 | 4/20 | 0.45 |
| ▸ | MMP16 | P51512 | 4/20 | 0.45 |
| ▸ | MMP1 | P03956 | 2/20 | 0.45 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 3/20 | 0.41 |
| ▸ | SLC9A1 | P19634 | 4/20 | 0.40 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.40 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2208256 | 0.84 | MMP2 (0.62) | MMP2MMP9MMP8MMP12MMP13 | |
| SCHEMBL1882671 | 0.81 | MMP2 (0.64) | MMP2MMP9MMP8MMP12MMP13 | |
| SCHEMBL9321170 | 0.80 | CXCL8 (0.54) | CXCL8EPHX1CYP3A4CYP2D6SLC6A2 | |
| SCHEMBL5140208 | 0.77 | L3MBTL1 (0.40) | MMP2MMP9MMP8MMP12MMP13 | |
| SCHEMBL28748849 | 0.77 | HTR2A (0.49) | MMP2MMP9MMP8MMP12MMP13 | |
| SCHEMBL1106525 | 0.77 | L3MBTL1 (0.52) | MMP2MMP9MMP8MMP12MMP13 | |
| SCHEMBL16316789 | 0.75 | CYP3A4 (0.43) | MMP2MMP9MMP8MMP12MMP13 | |
| SCHEMBL5673731 | 0.75 | L3MBTL1 (0.65) | CXCL8L3MBTL1 | |
| SCHEMBL966543 | 0.75 | L3MBTL1 (0.65) | CXCL8L3MBTL1 | |
| SCHEMBL16896807 | 0.73 | CES2 (0.37) | SLC9A1SLC9A2LOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338314-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2023-10-26 | — | — | US | disclosed |
| US-11648220-B2 | Methods for the treatment of myeloid derived suppressor cells related disorders | THE ROCKEFELLER UNIVERSITY (US) | 2023-05-16 | — | — | US | disclosed |
| US-20190029984-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2019-01-31 | — | — | US | disclosed |
| EP-3091970-A1 | LXR AGONISTS AND USES THEREOF | Rgenix, Inc. (US) | 2016-11-16 | — | — | EP | disclosed |
| WO-2015106164-A1 | LXR AGONISTS AND USES THEREOF | RGENIX, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648220-B2 | Methods for the treatment of myeloid derived suppressor cells related disorders | NR1H3, NR1H2, MCL1 | MMP2 4155/4885MMP9 3050/4885MMP8 834/4885 |
| US-20230338314-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | NR1H3, NR1H2, MCL1 | MMP2 4155/4885MMP9 3050/4885MMP8 834/4885 |
| US-20190029984-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | NR1H3, NR1H2, MCL1 | MMP2 4155/4885MMP9 3050/4885MMP8 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.